We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi’s Lixisenatide Diabetes Treatment Hits Phase III Endpoints
Sanofi’s Lixisenatide Diabetes Treatment Hits Phase III Endpoints
April 15, 2010
Sanofi-Aventis’ once-daily investigational drug lixisenatide for Type 2 diabetes met its primary endpoint in a Phase III trial by significantly
lowering HbA1c, a marker of blood glucose levels, compared with placebo.